What is VHB937?
VHB937 is a humanized monoclonal antibody (a lab-made antibody from identical cells that targets one specific antigen on a pathogen or diseased cell) that targets a receptor called TREM2 on microglia, special immune cells in the brain and spinal cord. By activating TREM2, VHB937 aims to enhance microglial function, (Immune cells in the brain that protect, clean up damage, and support repair) helping them remove damaged cells and support motor neuron health.
ASTRALS (VHB937) Trial:
How can I take part in this trial?
Trial sites and eligibility criteria are listed below. In order to take part in a clinical trial, you should first speak to your neurologist or MND Clinic.VHB937 is given as an intravenous (IV) infusion every four weeks during the 40-week study period.
Eligibility Criteria:
- MND diagnosed according to the Gold Coast diagnostic criteria
- First MND symptom within 24 months of screening
- Slow vital capacity (SVC) greater than 60% predicted
- Able to walk (with or without assistance) at screening
- No history of other neurological diseases
Exclusion Criteria:
- Current or prior use of non-invasive ventilation (NIV)
- Tracheostomy or use of gastrostomy tube for feeding
- Previous treatment with TREM2-targeting therapies
| NSW | Novartis Investigative Site - North Ryde | Worldwide contact: |
| NSW | Novartis Investigative Site - Randwick | |
| VIC | Novartis Investigative Site - Cauldfield | |
| QLD | Novartis Investigative Site - Herston | |
| QLD | Novartis Investigative Site - Southport |
Want to know more?
For more information visit the Study Details | A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) | ClinicalTrials.gov